ArticleMSMR2026
Number of tuberculosis tests and diagnoses of latent tuberculosis infection among U.S. army active component service members, January 2014-December 2023.
Article in MSMR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a force health protection threat to the U.S. military, particularly in crucial populations at increased risk of exposure or re-activation. This analysis examined TB testing trends and the prevalence of latent tuberculosis infection (LTBI) among U.S. Army active component soldiers from 2014 through 2023, the first decade following a major policy shift to targeted testing. Defense Medical Surveillance System data indicate that a total of 339,465 TB tests were administered, primarily (81.0%) tuberculin skin tests. Of those tests, 22,762 (6.7%) were positive, leading to the identification of 18,018 (5.3%) LTBI diagnoses. Asian/Pacific Islander soldiers demonstrated the highest LTBI diagnosis proportion (10.2%), followed by non-Hispanic Black (8.6%), Hispanic (5.6%), and Non-Hispanic White (2.9%) soldiers; the data also include 'other' (6.8%) and 'unknown/missing' (3.6%) categories. Recruits exhibited a significantly higher LTBI diagnosis proportion (11.0%) than non-recruits (3.6%), highlighting a high prevalence of LTBI among incoming personnel at time of accession. A marked decline in testing volume-a 72% decrease from 2014 to 2023 in the annual numbers of tests administered-followed the 2013 U.S. Army Medical Command policy shift. The substantially higher average proportion (6.7%) of positive tests from 2014 to 2023 compared to the average from the pre-policy era (1.3%) of universal screening demonstrates the successful concentration of testing resources on those most at risk, thereby improving diagnostic yield within a low-prevalence military force. This analysis's findings describe the epidemiological outcomes of the Army's targeted testing policy and underscore the importance of ongoing, targeted surveillance to mitigate TB risks in military settings. The 2013 policy that successfully transitioned the U.S. Army from universal tuberculosis screening to a targeted, risk-based strategy reduced testing volume by 72% over the next decade. The decline in tuberculosis testing volume coincided with a substantial increase in diagnostic yield, with the overall positivity proportion rising from 1.3% in the pre-policy era to 6.7% in 2023. The 2013 policy revision to a targeted, risk-based tuberculosis testing strategy succeeded in focusing valuable public health resources on high-risk groups. The high prevalence (14.0%) of latent tuberculosis infection that has been identified in recruits confirms that accession is the most critical juncture for tuberculosis control within the Army. Slight but notable differences in testing type positivity suggests opportunity for further policy refinement.
Indexed as
Identifiers
41805284PMC13075967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.